Femasys Inc. shares fall 4.99% intraday despite announcing the FemSperm Setup Kit for FemaSeed Intratubal Insemination.

Femasys Inc. dropped 4.99% intraday, despite the company announcing the introduction of its FemSperm Setup Kit, the first in a planned family of products designed to fully enable gynecologists for FemaSeed Intratubal Insemination. The setup kit includes customized components, such as a pre-configured centrifuge to optimize sperm preparation for use with FemaSeed. By providing a streamlined, in-office solution, Femasys is establishing the foundation for gynecologist-driven adoption of FemaSeed as a first-step fertility treatment, expanding patient access to alternatives ahead of IVF and advancing the Company’s commercialization strategy.